You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid: Donald Trump given experimental drug aimed at curbing severe illness

The new drug is in late-stage testing and its safety and effectiveness are not yet known

Topics
Donald Trump | Coronavirus Tests | Coronavirus

AP  |  Washington 

President Donald Trump speaks during a campaign rally at Arnold Palmer Regional Airport
President Donald Trump speaks during a campaign rally at Arnold Palmer Regional Airport

The experimental antibody drug given to President has been called one of the most promising approaches to preventing serious illness from a COVID-19 infection.

Its maker, Regeneron Pharmaceuticals Inc., said the company agreed to supply a single dose, given through an IV, for Trump at the request of his physician under compassionate use provisions, when an experimental medicine is provided on a case-by-case emergency basis, while studies of it continue.

The new drug is in late-stage testing and its safety and effectiveness are not yet known. No treatment has yet proved able to prevent serious illness after a infection.

Trump was given the experimental drug at the White House on Friday before he was taken to Walter Reed National Military Medical Center, where he'll be monitored, officials said. So far, Trump has had only mild symptoms, including fatigue.

Several physicians who treat COVID-19, including Dr. David Boulware at the University of Minnesota, had speculated that doctors might use the antibody drug, given that this approach has worked against other diseases in the past.

They're not going to just sit around and watch to see if he gets sick, Boulware said.

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it.

Vaccines trick the body into thinking there's an infection so it makes these antibodies.

But it can take weeks for them to form after natural infection or a vaccine. The drugs aim to give that protection immediately, by supplying concentrated versions of one or two antibodies that worked best against the in lab and animal tests.

Regeneron's drug contains two antibodies to enhance chances that it will work. The company previously developed a successful Ebola treatment from an antibody combo.

The drug is given as a one-time treatment through an IV. In multiple studies, Regeneron is testing it both for preventing infection and in people already infected, like Trump, to try to prevent serious illness or death.

Earlier this week, Regeneron said partial results from about 275 COVID-19 patients who were not sick enough to need hospitalization suggested it might be cutting how long symptoms last and helping reduce the amount of virus patients harbour.

However, the study has not been completed, the results were only announced in a company news release and have not been published or reviewed by other scientists.

Trump's physician, Dr. Sean Conley, said Trump also was taking zinc, vitamin D, an antacid called famotidine, melatonin and aspirin. None of those have been proven to be effective against COVID-19.

Trump apparently is not receiving hydroxychloroquine, a drug he widely promoted that has been shown in many studies to be ineffective for preventing or treating COVID-19.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 03 2020. 09:32 IST
RECOMMENDED FOR YOU